U.S. Markets open in 7 hrs 14 mins
  • S&P Futures

    3,902.00
    +4.25 (+0.11%)
     
  • Dow Futures

    31,241.00
    +39.00 (+0.12%)
     
  • Nasdaq Futures

    11,838.00
    -40.25 (-0.34%)
     
  • Russell 2000 Futures

    1,771.50
    -3.40 (-0.19%)
     
  • Crude Oil

    110.35
    +0.46 (+0.42%)
     
  • Gold

    1,845.10
    +3.90 (+0.21%)
     
  • Silver

    21.87
    -0.03 (-0.13%)
     
  • EUR/USD

    1.0562
    -0.0026 (-0.2429%)
     
  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     
  • Vix

    29.43
    +0.08 (+0.27%)
     
  • GBP/USD

    1.2495
    +0.0020 (+0.1587%)
     
  • USD/JPY

    127.8500
    +0.0560 (+0.0438%)
     
  • BTC-USD

    30,345.28
    +951.74 (+3.24%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a standard course of trastuzumab after surgery, and HER2 low patients, who did not receive trastuzumab after surgery.

  • 22.8% or 33 of the 145 patients reacted to GP2 at baseline with a positive immune response.

  • Of the 33 patients who did have a positive baseline DTH immune response to GP2, eight patients recurred, a recurrence rate of 24.2%, with a median time to recurrence of 99 days (0.27 years).

  • Of the 112 patients who did not have a positive DTH baseline immune response to GP2, 14 patients recurred a recurrence rate of 12.5%, with a median time to recurrence of 438 days (1.2 years).

  • If the patient completed the Primary Immunization Serie, the 5-year disease-free survival rate in the 46 HER2 3+ patients treated with GLSI-100 was 100% versus 89.4% in the 50 placebo patients treated with GM-CSF.

  • GLSI-100 was found to be well tolerated with no SAEs deemed related to study medication and elicited a potent immune response.

  • Injection site reactions were common, occurring in almost 100% of patients treated with either GLSI-100 or GM-CSF alone.

  • Price Action: GLSI shares are down 8.52% at $31.69 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.